Imunoviroterapia oncolítica com Herpesvírus Simplex tipo I em tumores cerebrais malignos
DOI:
https://doi.org/10.34119/bjhrv6n1-277Keywords:
Glioma, Herpesvirus 1, HSV-1, Neoplasmas Cerebral, Viroterapia OncolíticaAbstract
Os ensaios pré-clínicos e clínicos com vírus oncolíticos para o tratamento de tumores sólidos difíceis de gerir, tais como tumores cerebrais, provaram ser melhores do que os tratamentos convencionais. Especialmente para o glioblastoma (GB), um tumor cerebral com prognóstico e tratamento sombrios, são investigadas diferentes variantes do herpesvirus simplex tipo I e utilizadas para melhorar a sobrevivência a longo prazo. Objectivo: descrever a imunoviroterapia oncolítica com vírus do herpesvírus simplex tipo 1 como um agente imunitário e perturbador lítico em tumores cerebrais malignos. Método: a investigação é uma revisão abrangente dos artigos publicados entre 2013 e 2022, utilizando a estratégia PICO que integrou a questão da investigação. A pesquisa de informação foi realizada a partir de fontes de dados Pubmed e ScienceDirect, utilizando descritores e os operadores Booleanos AND e OR. Resultados: O vírus Herpes simplex tipo I confere particularidades cognatas para a matança de células cancerosas e cria imunidade inata e adaptativa contra células tumorais em cancros cerebrais em crianças e adultos.
References
Alayo, Q. A., Ito, H., Passaro, C., Zdioruk, M., Mahmoud, A. B., Grauwet, K., Zhang, X., Lawler, S. E., Reardon, D. A., Goins, W. F., Fernandez, S., Chiocca, E. A., & Nakashima, H. (2020). Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses. Scientific Reports, 10, 5095. https://doi.org/10.1038/s41598-020-61736-2
Aldrak, N., Alsaab, S., Algethami, A., Bhere, D., Wakimoto, H., Shah, K., Alomary, M. N., & Zaidan, N. (2021). Oncolytic Herpes Simplex Virus-Based Therapies for Cancer. Cells, 10(6), 1541. https://doi.org/10.3390/cells10061541
Bernstock, J. D., Hoffman, S. E., Chen, J. A., Gupta, S., Kappel, A. D., Smith, T. R., & Chiocca, E. A. (2021). The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies. Viruses, 13(6), 1158. https://doi.org/10.3390/v13061158
Bernstock, J. D., Vicario, N., Li, R., Nan, L., Totsch, S. K., Schlappi, C., Gessler, F., Han, X., Parenti, R., Beierle, E. A., Whitley, R. J., Aban, I., Gillespie, G. Y., Markert, J. M., & Friedman, G. K. (2020). Safety and Efficacy of Oncolytic HSV-1 G207 Inoculated into the Cerebellum of Mice. Cancer gene therapy, 27(3-4), 246-255. https://doi.org/10.1038/s41417-019-0091-0
Chalise, L., Kato, A., Ohno, M., Maeda, S., Yamamichi, A., Kuramitsu, S., Shiina, S., Takahashi, H., Ozone, S., Yamaguchi, J., Kato, Y., Rockenbach, Y., Natsume, A., & Todo, T. (2022). Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma. Molecular Therapy Oncolytics, 26, 265-274. https://doi.org/10.1016/j.omto.2022.07.006
Contreras, L. E. (2017). EPIDEMIOLOGÍA DE TUMORES CEREBRALES. Revista Médica Clínica Las Condes, 28(3), 332-338. https://doi.org/10.1016/j.rmclc.2017.05.001
Feola, S., Russo, S., Ylösmäki, E., & Cerullo, V. (2022). Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. Pharmacology & Therapeutics, 236, 108103. https://doi.org/10.1016/j.pharmthera.2021.108103
Foreman, P. M., Friedman, G. K., Cassady, K. A., & Markert, J. M. (2017). Oncolytic Virotherapy for the Treatment of Malignant Glioma. Neurotherapeutics, 14(2), 333-344. https://doi.org/10.1007/s13311-017-0516-0
Friedman, G. K., Bernstock, J. D., Chen, D., Nan, L., Moore, B. P., Kelly, V. M., Youngblood, S. L., Langford, C. P., Han, X., Ring, E. K., Beierle, E. A., Gillespie, G. Y., & Markert, J. M. (2018). Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Scientific Reports, 8, 13930. https://doi.org/10.1038/s41598-018-32353-x
Fukuhara, H., Takeshima, Y., & Todo, T. (2021). Triple‐mutated oncolytic herpes virus for treating both fast‐ and slow‐growing tumors. Cancer Science, 112(8), 3293-3301. https://doi.org/10.1111/cas.14981
Glorioso, J. C., Cohen, J. B., Goins, W. F., Hall, B., Jackson, J. W., Kohanbash, G., Amankulor, N., Kaur, B., Caligiuri, M. A., Chiocca, E. A., Holland, E. C., & Quéva, C. (2021). Oncolytic HSV Vectors and Anti-Tumor Immunity. Current Issues in Molecular Biology, 41, 381-468. https://doi.org/10.21775/cimb.041.381
Goradel, N. H., Alizadeh, A., Hosseinzadeh, S., Taghipour, M., Ghesmati, Z., Arashkia, A., & Negahdari, B. (2022). Oncolytic virotherapy as promising immunotherapy against cancer: Mechanisms of resistance to oncolytic viruses. Future Oncology (London, England), 18(2), 245-259. https://doi.org/10.2217/fon-2021-0802
Goradel, N. H., Baker, A. T., Arashkia, A., Ebrahimi, N., Ghorghanlu, S., & Negahdari, B. (2021). Oncolytic virotherapy: Challenges and solutions. Current Problems in Cancer, 45(1), 100639. https://doi.org/10.1016/j.currproblcancer.2020.100639
Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12(1), 31-46. https://doi.org/10.1158/2159-8290.CD-21-1059
Hausman, D. M. (2019). What Is Cancer? Perspectives in Biology and Medicine, 62(4), 778-784. https://doi.org/10.1353/pbm.2019.0046
Hemminki, O., dos Santos, J. M., & Hemminki, A. (2020). Oncolytic viruses for cancer immunotherapy. Journal of Hematology & Oncology, 13, 84. https://doi.org/10.1186/s13045-020-00922-1
Hong, B., Sahu, U., Mullarkey, M. P., & Kaur, B. (2022). Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors. Viruses, 14(1), 118. https://doi.org/10.3390/v14010118
Hu, P.-Y., Fan, X.-M., Zhang, Y.-N., Wang, S.-B., Wan, W.-J., Pan, H.-Y., & Mou, X.-Z. (2020). The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them. Applied Microbiology and Biotechnology, 104(19), 8231-8242. https://doi.org/10.1007/s00253-020-10802-w
Hua, L., & Wakimoto, H. (2019). Oncolytic herpes simplex virus therapy for malignant glioma: Current approaches to successful clinical application. Expert Opinion on Biological Therapy, 19(8), 845-854. https://doi.org/10.1080/14712598.2019.1614557
Jahan, N., Ghouse, S. M., Martuza, R. L., & Rabkin, S. D. (2021). In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV. Viruses, 13(9), 1740. https://doi.org/10.3390/v13091740
Lee, T. J., Nair, M., Banasavadi-Siddegowda, Y., Liu, J., Nallanagulagari, T., Jaime-Ramirez, A. C., Guo, J. Y., Quadri, H., Zhang, J., Bockhorst, K. H., Aghi, M. K., Carbonell, W. S., Kaur, B., & Yoo, J. Y. (2019). Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966. Molecular cancer therapeutics, 18(6), 1127-1136. https://doi.org/10.1158/1535-7163.MCT-18-0953
Lemos de Matos, A., Franco, L. S., & McFadden, G. (2020). Oncolytic Viruses and the Immune System: The Dynamic Duo. Molecular Therapy. Methods & Clinical Development, 17, 349-358. https://doi.org/10.1016/j.omtm.2020.01.001
Ma, J., Chen, C. C., & Li, M. (2021). Macrophages/Microglia in the Glioblastoma Tumor Microenvironment. International Journal of Molecular Sciences, 22(11), 5775. https://doi.org/10.3390/ijms22115775
Markert, J. M., Liechty, P. G., Wang, W., Gaston, S., Braz, E., Karrasch, M., Nabors, L. B., Markiewicz, M., Lakeman, A. D., Palmer, C. A., Parker, J. N., Whitley, R. J., & Gillespie, G. Y. (2009). Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM. Molecular Therapy: the Journal of the American Society of Gene Therapy, 17(1), 199-207. https://doi.org/10.1038/mt.2008.228
Markert, J. M., Razdan, S. N., Kuo, H.-C., Cantor, A., Knoll, A., Karrasch, M., Nabors, L. B., Markiewicz, M., Agee, B. S., Coleman, J. M., Lakeman, A. D., Palmer, C. A., Parker, J. N., Whitley, R. J., Weichselbaum, R. R., Fiveash, J. B., & Gillespie, G. Y. (2014). A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses. Molecular Therapy, 22(5), 1048-1055. https://doi.org/10.1038/mt.2014.22
Mazzacurati, L., Marzulli, M., Reinhart, B., Miyagawa, Y., Uchida, H., Goins, W. F., Li, A., Kaur, B., Caligiuri, M., Cripe, T., Chiocca, N., Amankulor, N., Cohen, J. B., Glorioso, J. C., & Grandi, P. (2015). Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV. Molecular Therapy, 23(1), 99-107. https://doi.org/10.1038/mt.2014.177
Meisen, W. H., Wohleb, E. S., Jaime-Ramirez, A. C., Bolyard, C., Yoo, J. Y., Russell, L., Hardcastle, J., Dubin, S., Muili, K., Yu, J., Caligiuri, M., Godbout, J., & Kaur, B. (2015). The impact of macrophage and microglia secreted TNFα on oncolytic HSV-1 therapy in the glioblastoma tumor microenvironment. Clinical cancer research : an official journal of the American Association for Cancer Research, 21(14), 3274-3285. https://doi.org/10.1158/1078-0432.CCR-14-3118
Miao, L., Fraefel, C., Sia, K. C., Newman, J. P., Mohamed-Bashir, S. A., Ng, W. H., & Lam, P. Y. P. (2014). The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy. British Journal of Cancer, 110(1), 94-106. https://doi.org/10.1038/bjc.2013.692
Nakashima, H., Kaufmann, J. K., Wang, P.-Y., Nguyen, T., Speranza, M. C., & Kasai, K. (2015). Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma—PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639993/
Okemoto, K., Wagner, B., Meisen, H., Haseley, A., Kaur, B., & Chiocca, E. A. (2013). STAT3 Activation Promotes Oncolytic HSV1 Replication in Glioma Cells. PLoS ONE, 8(8), e71932. https://doi.org/10.1371/journal.pone.0071932
Organización Mundial de la Salud. 2022.Cáncer. Recuperado 20 de septiembre de 2022, de https://www.who.int/es/news-room/fact-sheets/detail/cancer
Ostrom, Q. T., Francis, S. S., & Barnholtz-Sloan, J. S. (2021). Epidemiology of Brain and Other CNS Tumors. Current Neurology and Neuroscience Reports, 21(12), 68. https://doi.org/10.1007/s11910-021-01152-9
Otani, Y., Yoo, J. Y., Chao, S., Liu, J., Jaime-Ramirez, A. C., Lee, T. J., Hurwitz, B., Yan, Y., Dai, H., Glorioso, J. C., Caligiuri, M. A., Yu, J., & Kaur, B. (2020). Oncolytic HSV infected glioma cells activate NOTCH in adjacent tumor cells sensitizing tumors to gamma secretase inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(10), 2381-2392. https://doi.org/10.1158/1078-0432.CCR-19-3420
Otani, Y., Yoo, J. Y., Shimizu, T., Kurozumi, K., Date, I., & Kaur, B. (2022). Implications of immune cells in oncolytic herpes simplex virotherapy for glioma. Brain Tumor Pathology, 39(2), 57-64. https://doi.org/10.1007/s10014-022-00431-8
Rahman, M. M., & McFadden, G. (2021). Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy. Cancers, 13(21), 5452. https://doi.org/10.3390/cancers13215452
Raja, J., Ludwig, J. M., Gettinger, S. N., Schalper, K. A., & Kim, H. S. (2018). Oncolytic virus immunotherapy: Future prospects for oncology. Journal for Immunotherapy of Cancer, 6, 140. https://doi.org/10.1186/s40425-018-0458-z
Rius-Rocabert, S., García-Romero, N., García, A., Ayuso-Sacido, A., & Nistal-Villan, E. (2020). Oncolytic Virotherapy in Glioma Tumors. International Journal of Molecular Sciences, 21(20), E7604. https://doi.org/10.3390/ijms21207604
Roth, J. C., Cassady, K. A., Cody, J. J., Parker, J. N., Price, K. H., Coleman, J. M., Peggins, J. O., Noker, P. E., Powers, N. W., Grimes, S. D., Carroll, S. L., Gillespie, G. Y., Whitley, R. J., & Markert, J. M. (2014). Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Human Gene Therapy. Clinical Development, 25(1), 16-27. https://doi.org/10.1089/humc.2013.201
Saha, D., Martuza, R. L., & Rabkin, S. D. (2018). Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma. Immunotherapy, 10(9), 779-786. https://doi.org/10.2217/imt-2018-0009
Shi, T., Song, X., Wang, Y., Liu, F., & Wei, J. (2020). Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. Frontiers in Immunology, 11, 683. https://doi.org/10.3389/fimmu.2020.00683
Suryawanshi, Y. R., & Schulze, A. J. (2021). Oncolytic Viruses for Malignant Glioma: On the Verge of Success? Viruses, 13(7), 1294. https://doi.org/10.3390/v13071294
Todo, T., Ino, Y., Ohtsu, H., Shibahara, J., & Tanaka, M. (2022). A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma. Nature Communications, 13(1), 4119. https://doi.org/10.1038/s41467-022-31262-y
Todo, T., Ito, H., Ino, Y., Ohtsu, H., Ota, Y., Shibahara, J., & Tanaka, M. (2022). Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: A phase 2 trial. Nature Medicine, 28(8), 1630-1639. https://doi.org/10.1038/s41591-022-01897-x
Uche, I. K., Kousoulas, K. G., & Rider, P. J. F. (2021). The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment. Viruses, 13(7), 1200. https://doi.org/10.3390/v13071200
Wang, L.-B., Karpova, A., Gritsenko, M. A., Kyle, J. E., Cao, S., Li, Y., Rykunov, D., Colaprico, A., Rothstein, J. H., Hong, R., Stathias, V., Cornwell, M., Petralia, F., Wu, Y., Reva, B., Krug, K., Pugliese, P., Kawaler, E., Olsen, L. K., … Clinical Proteomic Tumor Analysis Consortium. (2021). Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell, 39(4), 509-528.e20. https://doi.org/10.1016/j.ccell.2021.01.006
Watanabe, N., McKenna, M. K., Rosewell Shaw, A., & Suzuki, M. (2020). Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Molecular Therapy: The Journal of the American Society of Gene Therapy, 29(2), 505-520. https://doi.org/10.1016/j.ymthe.2020.10.023
Yoo, J. Y., Swanner, J., Otani, Y., Nair, M., Park, F., Banasavadi-Siddegowda, Y., Liu, J., Jaime-Ramirez, A. C., Hong, B., Geng, F., Guo, D., Bystry, D., Phelphs, M., Quadri, H., Lee, T. J., & Kaur, B. (2019). Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo. Neuro-Oncology, 21(9), 1131-1140. https://doi.org/10.1093/neuonc/noz079
Zhang, S., & Rabkin, S. D. (2021). THE DISCOVERY AND DEVELOPMENT OF ONCOLYTIC VIRUSES: ARE THEY THE FUTURE OF CANCER IMMUNOTHERAPY? Expert Opinion on Drug Discovery, 16(4), 391. https://doi.org/10.1080/17460441.2021.1850689
